Anti-Amyloid Alzheimer’s Drugs Face New Doubts: Cochrane Review Finds ‘Trivial’ Effects
A bombshell Cochrane review questions the effectiveness of anti-amyloid Alzheimer’s drugs like Leqembi and Kisunla, calling their benefits “absent or trivial” despite FDA approvals. Cochrane Analysis: Little to No Clinical Benefit The nonprofit Cochrane compiled data from 17 placebo-controlled studies on seven amyloid-beta-targeting monoclonal antibodies, involving over 20,000 people with mild cognitive impairment or mild Alzheimer’s dementia.
Cochrane review anti-amyloid Alzheimer’s drugs Leqembi Kisunla trivial effects 2026
A bombshell Cochrane review questions the effectiveness of anti-amyloid Alzheimer’s drugs like Leqembi and Kisunla, calling their benefits “absent or trivial” despite FDA approvals.
Cochrane Analysis: Little to No Clinical Benefit
The nonprofit Cochrane compiled data from 17 placebo-controlled studies on seven amyloid-beta-targeting monoclonal antibodies, involving over 20,000 people with mild cognitive impairment or mild Alzheimer’s dementia.
Key findings at 18 months:
- Cognitive function: Probably little to no difference.
- Functional ability: Small effect at best.
- Dementia severity: May result in little to no difference.
“Successful removal of amyloid from the brain does not seem to be associated with clinically meaningful effects,” the researchers concluded. They urge focusing on other mechanisms beyond amyloid plaques.
Drugs reviewed include failed candidates like Aduhelm, bapineuzumab, crenezumab, gantenerumab, and solanezumab plus approved Leqembi (Biogen/Eisai) and Kisunla (Eli Lilly).
Also Read : 10 Heart-Healthy Ingredient Substitutions to Lower Cholesterol and Protect Your Heart
Pharma Pushback on Leqembi, Kisunla Effectiveness
Eli Lilly slammed the review’s methodology: “It pools data from unsuccessful molecules with approved medicines, artificially diluting benefits.”
Both Leqembi and Kisunla earned full FDA approvals after showing statistically significant reductions in clinical decline in their Phase 3 trials. Still, Cochrane highlights decades of amyloid-targeting setbacks, including 2022 revelations of fabricated research fueling skepticism.
Safety Concerns: Brain Swelling Risks Rise
The drugs “probably result in a small increase” in ARIA-E (brain swelling visible on MRI). Results on ARIA-H (brain bleeding) were too inconsistent for pooling.
Top drugmakers like Biogen, Eisai, and Lilly have invested over a decade in these therapies, securing three FDA nods but this review reignites debates on Alzheimer’s treatment efficacy.
Related Stories
Escaping the Healthcare Hamster Wheel: How Charles Gragg is Transforming Corporate Balance Sheets
Healthcare strategist, author, and professional speaker Charles Gragg has spent over 45 years exposing a brutal truth to the C-suite: if you buy traditional health insurance, you are merely renting a plan and handing a blank check to a monopoly. In this exclusive Pulse Magazine feature, Gragg breaks down his best-selling playbook, "Get Off the Hamster Wheel." He reveals how visionary employers are transitioning to self-funding, utilizing captive risk strategies, and leveraging continuous education to convert out-of-control healthcare liabilities into powerful corporate assets.
🚀 Fuel Your Next Move: Why MYND Sparkling Protein Water is Your New Must-Have!
Let’s be honest: finding a protein drink that is actually refreshing is tough. Most protein shakes are thick, heavy, and packed with artificial junk. Plus, considering the NIH estimates that 36% of people in the United States have lactose malabsorption, those traditional milky shakes can leave many of us feeling bloated and sluggish. That’s exactly why we are so excited to introduce you to a game-changer that is hitting our radar (and soon, your fridge): MYND Drinks.
How Claire J. Gilchrist's Frequency Balance™ Method Is Redefining Mental Health and Self-Empowerment Coaching
In the silence of the 2020 lockdowns, when the world stopped and most careers were suspended, Claire J. Gilchrist went inward. In this exclusive Pulse Magazine feature, the Founder of The Self-Empowerment Hub reveals why she stopped treating mental health, communication, and leadership as separate problems — and the trademarked framework she built instead. She shares the 48 subconscious behavioural patterns behind Frequency Balance™, why she refuses to "fix" her clients on principle, and the ethical distinction that shapes everything she does.